{"version":"1.0","provider_name":"Xspray","provider_url":"https:\/\/xspraypharma.com\/sv\/","author_name":"google@industritorget.se","author_url":"https:\/\/xspraypharma.com\/sv\/author\/googleindustritorget-se\/","title":"Xspray Pharma publicerar \u00e5rsredovisning f\u00f6r 2018 - Xspray","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"nr9pSZRxa3\"><a href=\"https:\/\/xspraypharma.com\/sv\/pressmeddelande\/xspray-pharma-publicerar-arsredovisning-for-2018\/\">Xspray Pharma publicerar \u00e5rsredovisning f\u00f6r 2018<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/xspraypharma.com\/sv\/pressmeddelande\/xspray-pharma-publicerar-arsredovisning-for-2018\/embed\/#?secret=nr9pSZRxa3\" width=\"600\" height=\"338\" title=\"\u201dXspray Pharma publicerar \u00e5rsredovisning f\u00f6r 2018\u201d &ndash; Xspray\" data-secret=\"nr9pSZRxa3\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"STOCKHOLM \u2013 29 april 2019. Xspray Pharma (Nasdaq First North: XSPRAY)\u00a0meddelar idag att bolagets \u00e5rsredovisning f\u00f6r r\u00e4kenskaps\u00e5ret 2018 har publicerats. \u00c5rsredovisningen bifogas och kan \u00e4ven laddas ner fr\u00e5n bolagets webbsida,\u00a0www.xspraypharma.com Engelsk version kommer att finnas tillg\u00e4nglig p\u00e5 bolagets webbsida inom kort.\u00a0 F\u00f6r ytterligare information, v\u00e4nligen kontakta: Per Andersson, vd, Xspray Pharma AB Mobil: +46 (0) [&hellip;]"}